Elevated osteopontin levels in mild cognitive impairment and Alzheimer's disease

Mediators of Inflammation

Volumn 2013, Issue , 2013, Pages

  Sun, Yuan ^a   Yin, Xue Song ^b   Guo, Hong ^c   Han, Rong Kun ^d   He, Rui Dong ^d   Chi, Li Jun ^d  

^a Bei Jing Daopei Hospital   (China)

^b HARBIN MEDICAL UNIVERSITY   (China)

^c Daqing Oilfield Hospital   (China)

^d THE FIRST AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

OSTEOPONTIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BLOOD SAMPLING; CEREBROSPINAL FLUID; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; BLOOD; MIDDLE AGED; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; OSTEOPONTIN;

EID: 84876567439     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2013/615745     Document Type: Article

References (45)

1. Blennow K., de Leon M. J., Zetterberg H., Alzheimer's disease. The Lancet 2006 368 9533 387 403 2-s2.0-33746310315 10.1016/S0140-6736(06)69113-7 (Pubitemid 44108123)
2. Hansson O., Zetterberg H., Buchhave P., Londos E., Blennow K., Minthon L., Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurology 2006 5 3 228 234 2-s2.0-32544435900 10.1016/S1474-4422(06)70355-6 (Pubitemid 43238346)
3. Morris J. C., Storandt M., McKeel D. W., Rubin E. H., Price J. L., Grant E. A., Berg L., Cerebral amyloid deposition and diffuse plaques in "normal" aging: evidence for presymptomatic and very mild Alzheimer's disease. Neurology 1996 46 3 707 719 2-s2.0-0029892175
4. Okello A., Edison P., Archer H. A., Turkheimer F. E., Kennedy J., Bullock R., Walker Z., Kennedy A., Fox N., Rossor M., Brooks D. J., Microglial activation and amyloid deposition in mild cognitive impairment: a PET study. Neurology 2009 72 1 56 62 2-s2.0-63849193695 10.1212/01.wnl.0000338622.27876.0d
5. Ciaramella A., Bizzoni F., Salani F., Vanni D., Spalletta G., Sanarico N., Vendetti S., Caltagirone C., Bossù P., Increased pro-inflammatory response by dendritic cells from patients with Alzheimer's disease. Journal of Alzheimer's Disease 2010 19 2 559 572 2-s2.0-77049111287 10.3233/JAD-2010-1257
6. Griffin W. S. T., Stanley L. C., Ling C., White L., MacLeod V., Perrot L. J., White C. L., Araoz C., Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proceedings of the National Academy of Sciences of the United States of America 1989 86 19 7611 7615 2-s2.0-0001360461 (Pubitemid 19254506)
7. Bergamaschini L., Canziani S., Bottasso B., Cugno M., Braidotti P., Agostoni A., Alzheimer's β -amyloid peptides can activate the early components of complement classical pathway in a C1q-independent manner. Clinical and Experimental Immunology 1999 115 3 526 533 2-s2.0-0033041151 10.1046/j.1365-2249.1999.00835.x (Pubitemid 29130371)
8. Nath A., Hall E., Tuzova M., Autoantibodies to amyloid beta-peptide (Abeta) are increased in Alzheime's disease patients and Abeta antibodies can enhance Abeta neurotoxicity: implications for disease pathogenesis and vaccine development. NeuroMolecular Medicine 2003 3 1 29 39 (Pubitemid 37070580)
9. Brody D. L., Holtzman D. M., Active and passive immunotherapy for neurodegenerative disorders. Annual Review of Neuroscience 2008 31 175 193 2-s2.0-47949132196 10.1146/annurev.neuro.31.060407.125529
10. Fisher L. W., Torchia D. A., Fohr B., Young M. F., Fedarko N. S., Flexible structures of SIBLING proteins, bone sialoprotein, and osteopontin. Biochemical and Biophysical Research Communications 2001 280 2 460 465 2-s2.0-0034801338 10.1006/bbrc.2000.4146 (Pubitemid 32912812)
11. Chellaiah M. A., Hruska K. A., The integrin α v β 3 and CD44 regulate the actions of osteopontin on osteoclast motility. Calcified Tissue International 2003 72 3 197 205 2-s2.0-0042855996 10.1007/s00223-002-1025-6 (Pubitemid 36919524)
12. Wang K. X., Denhardt D. T., Osteopontin: role in immune regulation and stress responses. Cytokine and Growth Factor Reviews 2008 19 5-6 333 345 2-s2.0-57049166456 10.1016/j.cytogfr.2008.08.001
13. Cho H. J., Kim H. S., Osteopontin: a multifunctional protein at the crossroads of inflammation, atherosclerosis, and vascular calcification. Current Atherosclerosis Reports 2009 11 3 206 213 2-s2.0-65449115666 10.1007/s11883-009-0032-8
14. Jansson M., Panoutsakopoulou V., Baker J., Klein L., Cantor H., Cutting edge: attenuated experimental autoimmune encephalomyelitis in ETA-1/osteopontin-deficient mice. Journal of Immunology 2002 168 5 2096 2099 2-s2.0-0036499086 (Pubitemid 34171807)
15. Chabas D., Baranzini S. E., Mitchell D., Bernard C. C. A., Rittling S. R., Denhardt D. T., Sobel R. A., Lock C., Karpuj M., Pedotti R., Heller R., Oksenberg J. R., Steinman L., The influence of the proinflammatory cytokine, osteopontin, on autoimmue demyelinating desease. Science 2001 294 5547 1731 1735 2-s2.0-0035941106 10.1126/science.1062960 (Pubitemid 33104847)
16. Petrow P. K., Hummel K. M., Schedel J., Franz J. K., Klein C. L., Müller-Ladner U., Kriegsmann J., Chang P.-L., Prince C. W., Gay R. E., Gay S., Expression of osteopontin messenger RNA and protein in rheumatoid arthritis: effects of osteopontin on the release of collagenase 1 from articular chondrocytes and synovial fibroblasts. Arthritis and Rheumatism 2000 43 7 1597 1605 10.1002/1529-0131(200007)43:7<1597::AID-ANR25>3.0.CO;2-0 (Pubitemid 30452481)
17. Mishima R., Takeshima F., Sawai T., Ohba K., Ohnita K., Isomoto H., Omagari K., Mizuta Y., Ozono Y., Kohno S., High plasma osteopontin levels in patients with inflammatory bowel disease. Journal of Clinical Gastroenterology 2007 41 2 167 172 2-s2.0-33846446710 10.1097/MCG.0b013e31802d6268 (Pubitemid 46148658)
18. Wong C. K., Lit L. C. W., Tam L. S., Li E. K., Lam C. W. K., Elevation of plasma osteopontin concentration is correlated with disease activity in patients with systemic lupus erythematosus. Rheumatology 2005 44 5 602 606 2-s2.0-21244447455 10.1093/rheumatology/keh558 (Pubitemid 41487227)
19. Weber G. F., Cantor H., Differential roles of osteopontin/Eta-1 in early and late lpr disease. Clinical and Experimental Immunology 2001 126 3 578 583 2-s2.0-0035655155 10.1046/j.1365-2249.2001.01702.x (Pubitemid 34008735)
20. Yokosaki Y., Tanaka K., Higashikawa F., Yamashita K., Eboshida A., Distinct structural requirements for binding of the integrins α v β 6, α v β 3, α v β 5, α 5 β 1 and α 9 β 1 to osteopontin. Matrix Biology 2005 24 6 418 427 2-s2.0-28844482875 10.1016/j.matbio.2005.05.005 (Pubitemid 41765020)
21. Weber G. F., Ashkar S., Glimcher M. J., Cantor H., Receptor-ligand interaction between CD44 and osteopontin (Eta-1). Science 1996 271 5248 509 512 2-s2.0-0030064334 (Pubitemid 26044470)
22. Cantor H., Shinohara M. L., Regulation of T-helper-cell lineage development by osteopontin: the inside story. Nature Reviews Immunology 2009 9 2 137 141 2-s2.0-58849083626 10.1038/nri2460
23. Chi L. J., Lu H. T., Li G. L., Wang X. M., Su Y., Xu W. H., Shen B. Z., Involvement of T helper type 17 and regulatory T cell activity in tumour immunology of bladder carcinoma. Clinical and Experimental Immunology 2010 161 3 480 489 2-s2.0-77955726968 10.1111/j.1365-2249.2010.04215.x
24. Chi L. J., Xu W. H., Zhang Z. W., Huang H. T., Zhang L. M., Zhou J., Distribution of Th17 cells and Th1 cells in peripheral blood and cerebrospinal fluid in chronic inflammatory demyelinating polyradiculoneuropathy. Journal of the Peripheral Nervous System 2010 15 4 345 356 2-s2.0-78650815791 10.1111/j.1529-8027.2010.00294.x
25. Hur E. M., Youssef S., Haws M. E., Zhang S. Y., Sobel R. A., Steinman L., Osteopontin-induced relapse and progression of autoimmune brain disease through enhanced survival of activated T cells. Nature Immunology 2007 8 1 74 83 2-s2.0-33846998653 10.1038/ni1415 (Pubitemid 46242361)
26. Carecchio M., Comi C., The role of osteopontin in neurodegenerative diseases. Journal of Alzheimer's Disease 2011 25 2 179 185 2-s2.0-79960720555 10.3233/JAD-2011-102151
27. Wung J. K., Perry G., Kowalski A., Harris P. L. R., Bishop G. M., Trivedi M. A., Johnson S. C., Smith M. A., Denhardt D. T., Atwood C. S., Increased expression of the remodeling- and tumorigenic-associated factor osteopontin in pyramidal neurons of the Alzheimer's disease brain. Current Alzheimer Research 2007 4 1 67 72 2-s2.0-33847131820 10.2174/156720507779939869 (Pubitemid 46293885)
28. Simonsen A. H., McGuire J., Hansson O., Zetterberg H., Podust V. N., Davies H. A., Waldemar G., Minthon L., Blennow K., Novel panel of cerebrospinal fluid biomarkers for the prediction of progression to Alzheimer dementia in patients with mild cognitive impairment. Archives of Neurology 2007 64 3 366 370 2-s2.0-33947287762 10.1001/archneur.64.3.366 (Pubitemid 46425690)
29. Comi C., Carecchio M., Chiocchetti A., Nicola S., Galimberti D., Fenoglio C., Cappellano G., Monaco F., Scarpini E., Dianzani U., Osteopontin is increased in the cerebrospinal fluid of patients with Alzheimer's disease and its levels correlate with cognitive decline. Journal of Alzheimer's Disease 2010 19 4 1143 1148 2-s2.0-77950356481 10.3233/JAD-2010-1309
30. Wirths O., Breyhan H., Marcello A., Cotel M. C., Brück W., Bayer T. A., Inflammatory changes are tightly associated with neurodegeneration in the brain and spinal cord of the APP/PS1KI mouse model of Alzheimer's disease. Neurobiology of Aging 2010 31 5 747 757 2-s2.0-77950530068 10.1016/j. neurobiolaging.2008.06.011
31. Folstein M. F., Folstein S. E., McHugh P. R., 'Mini mental state'. A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research 1975 12 3 189 198 2-s2.0-0016823810 10.1016/0022-3956(75)90026-6
32. McKhann G., Drachman D., Folstein M., Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984 34 7 939 944 2-s2.0-0021271971 (Pubitemid 14076461)
33. Diagnostic and Statistical Manual of Mental Disorders DSM-IV-R 1994 American Psychiatric Association
34. Hughes C. P., Berg L., Danziger W. L., A new clinical scale for the staging of dementia. British Journal of Psychiatry 1982 140 6 566 572 2-s2.0-0020040238 (Pubitemid 12124384)
35. Petersen R. C., Mild cognitive impairment as a diagnostic entity. Journal of Internal Medicine 2004 256 3 183 194 2-s2.0-4544335597 10.1111/j.1365-2796. 2004.01388.x (Pubitemid 39222988)
36. Winblad B., Palmer K., Kivipelto M., Jelic V., Fratiglioni L., Mild cognitive impairment: beyond controversies, towards a consensus. Journal of Internal Medicine 2004 256 3 181 182 2-s2.0-4544351982 10.1111/j.1365-2796.2004. 01382.x (Pubitemid 39222987)
37. Binder M., Christoph S., Sehnert B., Uhl M., Peter H.-H., Voll R. E., Warnatz K., Kollert F., Elevated serum osteopontin levels in idiopathic retroperitoneal fibrosis. Clinical and Experimental Rheumatology 2012 30 5 772 775
38. Comabella M., Pericot I., Goertsches R., Nos C., Castillo M., Blas Navarro J., Río J., Montalban X., Plasma osteopontin levels in multiple sclerosis. Journal of Neuroimmunology 2005 158 1-2 231 239 2-s2.0-10344246601 10.1016/j.jneuroim.2004.09.004 (Pubitemid 39626091)
39. Maetzler W., Berg D., Schalamberidze N., Melms A., Schott K., Mueller J. C., Liaw L., Gasser T., Nitsch C., Osteopontin is elevated in Parkinson's disease and its absence leads to reduced neurodegeneration in the MPTP model. Neurobiology of Disease 2007 25 3 473 482 2-s2.0-33847237667 10.1016/j.nbd.2006.10.020
40. Shinohara M. L., Kim J. H., Garcia V. A., Cantor H., Engagement of the type I interferon receptor on dendritic cells inhibits T helper 17 cell development: role of intracellular osteopontin. Immunity 2008 29 1 68 78 2-s2.0-44449146212 10.1016/j.immuni.2008.05.008
41. Saresella M., Calabrese E., Marventano I., Piancone F., Gatti A., Alberoni M., Nemni R., Clerici M., Increased activity of Th-17 and Th-9 lymphocytes and a skewing of the post-thymic differentiation pathway are seen in Alzheimer's disease. Brain, Behavior, and Immunity 2011 25 3 539 547 2-s2.0-79551687962 10.1016/j.bbi.2010.12.004
42. Neuroinflammation Working Group, Inflammation and Alzheimer's disease. Neurobiology of Aging 2000 21 3 383 421
43. Ringman J. M., Schulman H., Becker C., Jones T., Bai Y., Immermann F., Cole G., Sokolow S., Gylys K., Geschwind D. H., Cummings J. L., Wan H. I., Proteomic changes in cerebrospinal fluid of presymptomatic and affected persons carrying familial Alzheimer disease mutations. Archives of Neurology 2012 69 1 96 104 10.1001/archneurol.2011.642
44. Maetzler W., Michelis J., Tomiuk J., Melms A., Becker C., Gasser T., Schulte C., Berg D., A single-nucleotide polymorphism of the osteopontin gene may contribute to a susceptibility to Lewy body disease. Journal of Neural Transmission 2009 116 5 599 605 2-s2.0-67349248498 10.1007/s00702-009-0209-x
45. Town T., Tan J., Flavell R. A., Mullan M., T-cells in Alzheimer's disease. NeuroMolecular Medicine 2005 7 3 255 264 10.1385/NMM:7:3:255 (Pubitemid 41507148)